ProMPT Renewal

Lead Research Organisation: University of Cambridge
Department Name: Oncology

Abstract

Prostate cancer is the commonest solid tumour in men. We deperately need biomarkers that predict how in the future an individual cancer is likely to behave. The development of a clinically linked repository across the two prostate cancer collaboratives is critical in achieving this, and will underpin the science that is funded through more conventional routes.

Technical Summary

The two prostate cancer collaboratives are moving towards the provision of infrastructure only for the remaining two years of the funding. We are concentrating on developing a clinically linked bio-bank for prostate cancer for tissue, nucleic acids, and paraffin embedded tissue, as well as liquid based collections.

Publications

10 25 50
publication icon
Harmenberg U (2011) Curative radiation therapy in prostate cancer. in Acta oncologica (Stockholm, Sweden)

publication icon
Pellacani D (2013) Prominin-1 (CD133) Expression in the Prostate and Prostate Cancer: A Marker for Quiescent Stem Cells. in Advances in experimental medicine and biology

publication icon
Frame FM (2011) Cancer stem cells, models of study and implications of therapy resistance mechanisms. in Advances in experimental medicine and biology

publication icon
Maitland NJ (2013) A fusion at the root of prostate cancer. in Asian journal of andrology

publication icon
Anandadas CN (2011) Early prostate cancer--which treatment do men prefer and why? in BJU international

 
Description Bristol - CRUK Population Research Committee Member
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Influence on policy and funding by the CRUK Population Research Committee
 
Description Bristol - Epidemiology Course
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Cancer Epidemiology 3 day short course
 
Description Bristol - Member of National Awareness and Early Diagnosis Initiative
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Input and influence to this national committee
 
Description Cambridge - National Prostate Audit
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Prof Neal has led a consortium to obtain funding for a prostate cancer audit supported by a number of stakeholders including BAUS, BAUN, BUG and others. This will be substantial funding over the next quinquennium and will directly improve prostate cancer care.
 
Description Cambridge - Prostate Cancer Advisory Group - Screening Policy Group
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Recent editorials from Professor Neal are now being considered by the Screening Policy Group at the Dept of Health.
 
Description Glasgow - National Prostate Cancer Quality Performance Indicator Development Group Scotland
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
Impact Influence and input to this committee
 
Description Glasgow - Trustee for Prostate Cancer Charity
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Influence to this Charity
 
Description Newcastle - Member of NCRI Biomarkers and Imaging Group
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Influence and input to this committee
 
Description Newcastle - NCRI Prostate Clinical Studies Group
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Influence and input to this committee
 
Description Newcastle - Prostate Cancer Charity SAC
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Influence and input to this committee
 
Description Oxford - Biomedical Research Centre/Oxford Radcliffe Bio-Repository
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
Impact Invited to join steering committee of Oxford Biomedical Research Centre and Oxford Radcliffe Biorepository
 
Description Oxford - Deutsch Kerbshilfe
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
Impact Invited to strategy discussions/meetings Deutsch Kerbshilfe, Germany (National Cancer Charity)
 
Description Oxford - French Ministry
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
Impact External speaker/advisor, French Ministry, Convention on Health Analysis and Management
 
Description Oxford - Gothenburg University
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
Impact RAE equivalent and external review
 
Description Oxford - Member of HTA Commissioning Board
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Member of HTA Commissioning Board
 
Description Oxford - NCI USA
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
Impact Invited to advice on biobanking policies
 
Description York - Association of Medical Research Charities
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
Impact Presented to and shared in the evolution of a policy document from the Association of Medical Research Charities on academic spin out companies and intellectual property.
 
Description York - Chair - French Prostate Cancer Committee
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
Impact not known
 
Description York - Kuwaiti and Qatari National Research Programme Advisor
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
Impact not known
 
Description York - Scientific Chair of the Orchid Trust (LONDON)
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact not known
 
Description Bristol - BMA Gunton Award
Amount £34,803 (GBP)
Organisation British Medical Association (BMA) 
Sector Learned Society
Country United Kingdom
Start 09/2010 
End 09/2013
 
Description Bristol - CRUK
Amount £189,534 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2012 
End 12/2014
 
Description Bristol - NIHR
Amount £4,500,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2012 
End 03/2016
 
Description Bristol - NIHR
Amount £319,815 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2011 
End 06/2013
 
Description Bristol - WCRF
Amount £224,387 (GBP)
Organisation World Cancer Research Fund 
Sector Charity/Non Profit
Country Global
Start 04/2012 
End 03/2015
 
Description Bristol charity - Above & Beyond
Amount £44,840 (GBP)
Organisation University Hospitals Bristol NHS Foundation Trust 
Department Above and Beyond Grants
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2012
 
Description Cambridge - CANCURE (2m euros across 11 participants)
Amount £188,564 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 07/2006 
End 06/2010
 
Description Cambridge - CRUK Programme Grant
Amount £1,439,674 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2010 
End 03/2015
 
Description Cambridge - CRUK TRICC
Amount £525,098 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 12/2012
 
Description Cambridge - Cytosystems
Amount £100,747 (GBP)
Organisation Cytosystems Ltd 
Sector Private
Country United Kingdom
Start 04/2009 
End 05/2011
 
Description Cambridge - ICGC - next generation sequencing
Amount £500,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 12/2013
 
Description Cambridge - NIHR Senior Investigator Award
Amount £75,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2008 
End 03/2013
 
Description Cambridge - National Institute of Health
Amount £48,425 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 07/2010 
End 06/2011
 
Description Cambridge - PHILIPS
Amount £207,000 (GBP)
Organisation Koninklijke Philips Electronics N.V. 
Department Philips
Sector Private
Country Global
Start 07/2007 
End 12/2012
 
Description Cambridge - ProMark
Amount £341,510 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2008 
End 12/2012
 
Description Cambridge Cancer Research Fund
Amount £176,237 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 06/2010 
End 05/2013
 
Description Cambridge/Bristol/Oxford - CAP
Amount £1,125,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 12/2012
 
Description Cambridge/Bristol/Oxford - NIHR, HTA, ProtecT
Amount £13,700,000 (GBP)
Organisation National Institute for Health Research 
Department Health Technology Assessment Programme (HTA)
Sector Public
Country United Kingdom
Start 01/2009 
End 12/2013
 
Description Newcastle - CRUK
Amount £220,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2012 
End 01/2016
 
Description Newcastle - Prostate Cancer Charity
Amount £198,000 (GBP)
Organisation Prostate Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2010 
End 09/2013
 
Description Newcastle - Sanofi Aventis
Amount £175,000 (GBP)
Organisation Sanofi 
Department Aventis
Sector Private
Country France
Start  
 
Description Newcastle CRUK/AstraZeneca/CRUK/AstraZeneca jointly
Amount £120,000 (GBP)
Organisation Autistica 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description Oxford - NIHR Senior Investigator award
Amount £125,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description Oxford - Pro-nest
Amount £526,925 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2010 
End 12/2013
 
Description Oxford - Prostate Cancer Charity
Amount £248,975 (GBP)
Organisation Prostate Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description York - Yorkshire Cancer Research
Amount £2,200,000 (GBP)
Organisation Yorkshire Cancer Research 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description York - Yorkshire Cancer Research
Amount £210,000 (GBP)
Organisation Yorkshire Cancer Research 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Title Bristol - GWAS controls 
Description 1500 cases and controls nested within ProtecT Study 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact Contribution to papers on GWAS (x2 Nature Genetics; xa JNCI) 
 
Title Bristol - Phenotypes nested within ProtecT Study case control study 
Description Database of the following phenotypes nested within the ProtecT study case-control study: components of the IGF system, n=3000 cases and 3000 controls (IGF-I, IGF-II, IGFBP-2, IGFBP-3); vitamins D, A, E, folate, B12, homocystein, n=1500 cases and 1500 controls. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact Published output on IGFs 
 
Title Cambridge - CANCAP 
Description The previously funded CANCAP project jointly between Cooper and Neal is now being analysed and will include CGH array technology and SNP6 results which again when published will be available as a public resource. 
Type Of Material Data analysis technique 
Provided To Others? No  
Impact The previously funded CANCAP project jointly between Cooper and Neal is now being analysed and will include CGH array technology and SNP6 results which again when published will be available as a public resource. 
 
Title Cambridge - Prostate Cancer collections - collaboration with Southern Collaborative 
Description Joint database for prostate cancer collections funded under ProMPT is being set up together with the Sountern Collaborative. The database will go live to offer researchers the opportunity to send in bids to access specimens in the excess specimens collected as part of ProMPT 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact New web-based access for tissue just activated 
 
Title Cambridge - high throughput sequencing 
Description Several resources put on line from high throughput sequencing for ChIP sequencing (EMBOJ paper Massie et al). High throughput sequencing available for local ProMPT members including data from paraffin embedded material and initial date from next generation sequencing. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact Several resources put on line from high throughput sequencing for ChIP sequencing (EMBOJ paper Massie et al). High throughput sequencing available for local ProMPT members including data from paraffin embedded material and initial date from next generation sequencing. 
 
Title Glasgow - Docetaxel resistant prostate cancer cells 
Description Used among collaborating centres within ProMPT 
Type Of Material Cell line 
Provided To Others? No  
Impact new collaborative projects in train 
 
Title Newcastle - siRNA library screens and assay development for p68 
Description Medium scale siRNA library screens and assay development for HTS Specific Phospho-p68 antibody generated 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Medium scale siRNA library screens and assay development for HTS Specific Phospho-p68 antibody generated 
 
Title Newcastle - tissue microarray 
Description Further expansion of prostate cancer tissue microarray 
Type Of Material Data analysis technique 
Provided To Others? No  
Impact not known 
 
Title Oxford - New Ethics Approval for bone marrow/bone biopsy 
Description Ethics approval that has made anew line of enquiry possible. 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact New ethics approval for collection of bone marrow/bone biopsies prospectively from prostate cancer patients to study bone microenvironment. 
 
Title Oxford - artificial intelligence 
Description artificial intelligence (fuzzy logic) 
Type Of Material Data analysis technique 
Provided To Others? No  
Impact Continuing development of artificial intelligence (fuzzy logic) to interpret clinicopathological data to predict disease outcome, and large array data analysis. 
 
Title Oxford - new Surgical Oncology section 
Description new research section 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact Establishment of Surgical Oncology as new section of the CRUK Oxford Cancer Research Centre 
 
Title York - PTT273 
Description Generation of >100 monoclonal antibodies against a prostate cancer stem cell target PTT273. Of these, 3 were selected with the highest PTT273 enzyme inhibiting activity which were able to co-select with the AC133 antibody for CSC's in primary tissue. However, affinity was insufficient to use for in vivo inhibition experiments (this was largely funded and carried out in Pro-Cure Therapeutics as part of our therapeutic development programme) 
Type Of Material Antibody 
Provided To Others? No  
Impact Start up funding for new biotech company 
 
Title York - PTT273 
Description We have 3 highly specific, but relatively low affinity monoclonal antibodies against a prostate cancer stem cell antigen PTT273, and have generated recombinant protein from this antigen for ELISA on human sera, and sufficient (4mg) of human cell derived protein from another potential CSC antigen PTT256 for monoclonal antibody production (Pro-Cure Therapeutics). 
Type Of Material Model of mechanisms or symptoms - human 
Provided To Others? No  
Impact start up funding for new biotech company 
 
Title York - Xenograft 
Description We have developed a new and relevant in vivo xenograft model for prostate cancer in immunocompromised mice (Rag2-/-, GammaC -/-). We are able to serially transplant and to freeze tumour cell aliquots from an original tissue fragment, expanding both the tumour initiating cell population, and providing a testing tool (IP filed by Pro-Cure Therapeutics ) for novel therapeutics. In this model true Gleason grade 6 cancer are NOT tumorigenic, mirroring clinical outcome in human patients, where a Gleason grade 7 (or the presence of a pattern 4 is synonymous with bad prognosis). We now have 15 near patient serially transplantable tumours from both hormone sensitive and castration resistant tumours. 
Type Of Material Model of mechanisms or symptoms - human 
Provided To Others? No  
Impact We now have 15 near patient serially transplantable tumours from both hormone sensitive and castration resistant tumours. 
 
Title York - Xenografts 
Description 1. A series of primary xenografts from patients with Gleason grade 7+ tumours and castration resistant recurrences, with back up of lymphocyte and primary cell cultures from the same patients. 2. A truly malignant xenograft model of prostate cancer primary tissues. 3. The ability to freeze and regraft fractionated human epithelial cells from xenografts 
Type Of Material Model of mechanisms or symptoms - human 
Provided To Others? No  
Impact Studies underway to carry out expression profiling 
 
Title York - YCSSA bioinformatics tool 
Description As part of a collaboration with the York System for Complex System Analysis (YCSSA) we have developed new bioinformatics tools to analyse gene expression datasets, as applied to prostate differentiation. This was funded by a pump-priming grant from YCR. Some of the primary data analysed was generated during and supported in part by the Prompt project. 
Type Of Material Data analysis technique 
Provided To Others? No  
Impact Funding from YCR 
 
Title York - microRNA 
Description We have generated (in collaboration with Univ of Tampere) a microRNA expression database from fractionated cell populations from Normal, malignant and castration-resistant prostate cancer. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact We have generated (in collaboration with Univ of Tampere) a microRNA expression database from fractionated cell populations from Normal, malignant and castration-resistant prostate cancer. 
 
Title York - software tools 
Description We have developed new software tools for (i) in silico modelling of prostate epithelial differentiation and cell fate and (ii) Analysis of candidate prostate cancer genes in 'big datasets' , to identify coregulated genes (IP filed here by Univ of York) 
Type Of Material Data analysis technique 
Provided To Others? No  
Impact not known 
 
Description Bristol - Role of Fascin in prostate cancer prevention 
Organisation University of Bristol
Department School of Biochemistry Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-supervision of PhD Student
Collaborator Contribution Professor Richard Martin has developed a collaboration with Professor Jo Adams (Dept of Biochemistry, University of Bristol) to investigate the role of fascin in prostate cancer prevention. They are co-supervising a Wellcome Trust funded PhD student to undertake the work.
Impact Ongoing work towards PhD
Start Year 2010
 
Description Cambridge - Colin Cooper - Whole Genome Sequencing 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Development of idea; careful development of methodologies for tissue processing; will be contributing a major number of cases
Collaborator Contribution Collaboration with Colin Cooper to put in a request to CRUK for funding for whole genome sequencing for prostate cancer. This is likely to lead to a very major award and a major impact on prastate cancer practice.
Impact Grant application due to be announced 1st week in December
Start Year 2010
 
Description Cambridge - EC Funding 
Organisation deCODE genetics
Country Iceland 
Sector Private 
PI Contribution Running clinical studies group
Collaborator Contribution collaboration with other EC departments
Impact Grant awarded from EC
Start Year 2008
 
Description Cambridge - GSK Novel metabolic inhibitors 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution joint exchange of know how
Collaborator Contribution joint exchange of know how to look at novel metabolic inhibitors involved in prostate cancer. Currently pre-clinical and involving novel imaging technologies. (C11 acetate but likely to move to man in the near future)
Impact To look at novel metabolic inhibitors involved in prostate cancer. Currently pre-clinical and involving novel imaging technologies (C11 acetate but likely to move to man in the near future).
Start Year 2011
 
Description Cambridge - ICOGS, PRACTICAL, NIH Consortium 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution DNA from our collections formed a significant number of the cases and controls
Collaborator Contribution Request to join in collaborations within Europe, Australia and the US for prostate cancer whole genome sequencing. We are now formally a part of a number of collaborations which are funded including ICOGS, PRACTICAL and a NIH consortium
Impact See publications (x2 Nature Genetics; x1 JNCI plus others)
Start Year 2010
 
Description Cambridge - NCI - functional effects of SNPs 
Organisation Dana-Farber Cancer Institute
Department Department of Medical Oncology
Country United States 
Sector Academic/University 
PI Contribution Collaboration on laboratory work with Dana Faber
Collaborator Contribution verification of expression data in prostate cancer
Impact Awarded grant from NCI
Start Year 2010
 
Description Cambridge / ICR / Marsden - Next Generation Sequencing 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Next generation sequencing. This is a proof of principle study which if goes ahead will result in £16.5 million extra funding.
Collaborator Contribution joint exchange of know howjoint exchange of know how
Impact na
Start Year 2011
 
Description Cambridge / ICR / Marsden - Next Generation Sequencing 
Organisation Royal Marsden NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Next generation sequencing. This is a proof of principle study which if goes ahead will result in £16.5 million extra funding.
Collaborator Contribution joint exchange of know howjoint exchange of know how
Impact na
Start Year 2011
 
Description Glasgow - ERK5 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with TAPG on ERK5 expression analysis
Impact not known
Start Year 2010
 
Description Newcastle - AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Developing further collaboration iwht AstraZeneca using novel androgen receptor antagonists they have developed.
Impact not known
Start Year 2010
 
Description Newcastle - Biosignatures 
Organisation Biosignatures Ltd
Country United Kingdom 
Sector Private 
PI Contribution A company with specialist bioinformatics expertise. Defining a protein signature for prostate cancer patients using blood samples and 2D gel electrophoresis. Possible access to stored blood samples from ProtecT/ProMPT.
Impact not known
Start Year 2011
 
Description Newcastle - ICL 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with the Bevan Group at ICL - included use of prostae cancer tissue microarray and led to publication of research in Cancer Research
Impact not known
Start Year 2011
 
Description Oxford - CARIS epigenetics project 
Organisation CARIS Life Sciences
Country United States 
Sector Private 
PI Contribution Novel project studying methylation in prostate cancer. We are providing a well-annotated bio-repository.
Collaborator Contribution Epigenetics project in prostate cancer
Impact New funded project
Start Year 2010
 
Description Oxford - Data Unification 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Data Unification for prostate cancer database on ProMPT/ProtecT patients between Northern and Southern Collaboratives
Collaborator Contribution Data Unfiication between ICR, Cambridge and Oxford
Impact New website opened in November
Start Year 2009
 
Description Oxford - MSKCC New York 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Provision of data from Protect / ProMPT
Collaborator Contribution Collaboration on prostate cancer prediction using PSA
Impact Vickers et al Clin Cancer Res 2010
Start Year 2010
 
Description Oxford / Cambridge / Bristol 
Organisation University of Oxford
Department Nuffield Department of Surgical Sciences Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution joint exchange of know how
Collaborator Contribution Submission of an outline application to carry out studies of novel diagnositc pathways including the role of SNPs and gentyping to NIHR
Impact Submission of an outline application to carry out studies of novel diagnositc pathways including the role of SNPs and gentyping to NIHR
Start Year 2011
 
Description Oxford/Cambridge - collaboration with Henrik Gronberg Karolinska Institute 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution TMAs received from Karolinska for novel biomarker studies Tissue being sent to Karolinska for expression studies
Collaborator Contribution Joint exchange of know how
Impact New meeting in Oxford in 2011 to take this project forward
Start Year 2010
 
Description Oxford/Cambridge/Stockholm 
Organisation Karolinska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution To look at SNP profiling and new diagnostic pathways in prostate cancer.
Collaborator Contribution To look at SNP profiling and new diagnostic pathways in prostate cancer. Possible application to European Union funding. Joint exchange of know how
Impact New meeting in Cambridge in 2012
Start Year 2011
 
Description York - Toronto : Radiation sensitivity of prostate cancer stem cells 
Organisation University of Toronto
Department Department of Medical Biophysics
Country Canada 
Sector Academic/University 
PI Contribution Radiation sensitivity of prostate cancer stem cells
Impact not known
Start Year 2010
 
Title Cambridge - MSMB assay 
Description Recent publication in PLoS One made the front page of the Daily Mail and Daily Telegraph. IP discussions are taking place with a company to discuss the MSMB assay. 
IP Reference  
Protection Protection not required
Year Protection Granted 2010
Licensed No
Impact Paper in PLOSOne
 
Title Cambridge - two novel biomarkers 
Description Two new novel biomarkers which will be prognostic are being taken through by Cancer Research Technologies to IP protection 
IP Reference  
Protection Protection not required
Year Protection Granted 2011
Licensed Commercial In Confidence
Impact na
 
Title York - HIP 0072 
Description The patent discloses a genetically engineered baculovirus biotherapy vector that is modified to target the baculovirus to a cell that expresses either gonadotropin receptor or neurotensin receptor (i.e. the prostate). 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative reserach with other groups.
 
Title York - HIP0068 
Description The application discloses the full array data generated from CD133+ prostate cancer stem cells. Claims have been limited to PTT273 as a prostate CSC marker; siRNAs derived from PTT273; vaccines comprising PTT273 and methods to screen for agents that inhibit PTT273. Divisional application strategy in play, to sequentially protect subsequent targets, agents against them and diagnostics for them. 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP0069 
Description The patent discloses the isolation and characterization of an enriched population of CD133+ cancer stem cells; pure cell cultures of prostate CSCs; animal models containing them; cell based vaccine compositions amongst other claims. 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP0073 
Description The patent discloses a method for the growth and maintenance of cancerous prostate acini and their use in drug screening 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP1689 
Description Discloses antagonists of PTT521, specifically nucleic-acid based (e.g. siRNA), which induces cancer stem/progenitor cells to differentiate and stop dividing. The claims are also directed to liposome delivery of siRNA. 
IP Reference  
Protection Protection not required
Year Protection Granted 2008
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP1709 
Description The applications disclose vaccine compositions comprising PTT273 and fragments derived from PTT273 and their use in the treatment of cancer, specifically prostate cancer. 
IP Reference US20120100102 
Protection Patent granted
Year Protection Granted 2012
Licensed Commercial In Confidence
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP3497 
Description The application relates to a modified baculovirus that targets PTT521 inhibitory RNA (e.g. siRNA, antisense RNA, micro RNA) to prostate cancer cells. 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP3787 
Description Claims agents that inhibit the expression or activity of PTT522, including methods to treat cancer using the agents. 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - HIP4039 
Description This application covers non-human mammalian models, and processes to produce them, for the analysis of cancer stem cells and the use of the models in the identification and validation of agents useful in the treatment of cancer. 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed No
Impact Facilitation of collaborative research with other groups.
 
Title York - PCT filing 
Description New PCT filing (PCT/GB2011/051913) relating to a group of genes that could serve as markers of prostate cancer and possible targets for therapeutic intervention. 
IP Reference WO2012046064 
Protection Patent granted
Year Protection Granted 2012
Licensed No
Impact see above
 
Title York - various applications 
Description Total of more than 30 worldwide applications in prostate biology and cancer stem cells currently being progressed (mostly transferred to University Spin out company Pro-Cure Therapeutics). Key patents on Prostate 3D modelling have granted in USA, Europe and UK, and Cancer stem cell isolation has granted in UK, Europe awaiting grant in USA, Japan, Australia, Canada. 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed Commercial In Confidence
Impact see above
 
Title ELISA for MSMB 
Description Measurement of MSMB to diagnose prostate cancer 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2010
Development Status Actively seeking support
Impact Paper in PLOS one; continued validation and interaction with several companies 
 
Title York - SiRNA inhibition 
Description We have demonstrated the effectiveness of inhibition of a number of potential cancer stem cell targets by SiRNA inhibition in animal models. Again a number of patents to cover this have been filed (by Pro-Cure Therapeutics) 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Actively seeking support
Impact We have demonstrated the effectiveness of inhibition of a number of potential cancer stem cell targets by SiRNA inhibition in animal models. Again a number of patents to cover this have been filed (by Pro-Cure Therapeutics) 
 
Title York - monoclonal antibodies target gene PTT273 
Description Initial results were promisiing, but later problem were identified 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Initial development
Year Development Stage Completed 2009
Development Status Closed
Impact Some funding initially by spin-out company 
 
Title York - series of siRNA reagents 
Description siRNA against cancer stem cells 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Initial development
Year Development Stage Completed 2010
Development Status Actively seeking support
Impact ongoing develoment 
 
Title York - vaccine 
Description We have co-developed a vaccine (still at animal experimental stage) against prostate cancer stem cells with the University of Sheffield. IP has been filed jointly. 
Type Therapeutic Intervention - Vaccines
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact We have co-developed a vaccine (still at animal experimental stage) against prostate cancer stem cells with the University of Sheffield. IP has been filed jointly. 
 
Company Name Newcastle - NEPAF 
Description Collaboration with local proteomics company to investigate protein components of the androgen receptor signalling cascade. 
Year Established 2010 
Impact Already led to one publication (Gaughan et al 2010)
 
Company Name Pro-Cure Therapeutics Ltd 
Description Pro-Cure therapeutics has spun out of our laboratory. 10 scientists at present. Currently negotiating research agreements with two major pharma companies. 
Year Established 2010 
Impact Novel company employing people in York • Pro-Cure Therapeutics, my spin out company has continued trading and employing 12 scientists, through difficult times in 2011. The loss of a multi-million pound contract with a major pharma company through policy changes at the parent company, and after extensive 12 months' due diligence has placed the company in severe financial difficulty, and the shareholders have decided to put it up for sale (August 2011). This process is now well under way.
Website http://www.pro-cure.uk.com/
 
Description Cambridge - CRUK Cambridge Research Institute 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Dr Hayley Whitaker regularly presents to non-academic audiences who are interested in the translational research being carried out at the Institute.

None
Year(s) Of Engagement Activity 2010
 
Description Cambridge - lay audiences and media 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact various lay audiences locally and nationally

NA
Year(s) Of Engagement Activity 2011
 
Description Cambridgeshire Prostate Cancer Support Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact 200 patients and family members attended a talk on the translational research programmes

None
Year(s) Of Engagement Activity 2010
 
Description Newcastle - CRUK Fundraising Event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Two large organised CRUK Fundraising events that mentioned MRC funded research

additional grant funding for the group
Year(s) Of Engagement Activity 2010
 
Description Newcastle - Northern Institute for Cancer Research Open Day 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Presentations to local fundraisers

not known
Year(s) Of Engagement Activity 2010
 
Description Newcastle - Presentation Rotterdam, Amsterdam, ICR, Washington 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Presentations at conferences in Rotterdam, Amsterdam, ICR and Washington

Not known
Year(s) Of Engagement Activity 2010
 
Description Newcastle - Race for Life 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact short talks and discussions at Regional Cancer Charity fund raising events - Race for Life (Newcastle and Gateshead)

na
Year(s) Of Engagement Activity 2011
 
Description York - BBC Local Radio 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Review of the newspapers on the local BBC Radio station giving a scientific point of view and selecting articles of scientific interest to the general public

NA
Year(s) Of Engagement Activity 2011
 
Description York - Laboratory open evenings 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact My group have presented public information lectures at laboratory open evenings. On each evening, 3 graduate students gave short accounts of their thesis research followed by question and answer sessions and a guided tour of the Department with demonstrations of some key (and stimulating) technology.

na
Year(s) Of Engagement Activity 2011
 
Description York - Local patient support group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Presentation of output of our research to a local patient support group at York Hospital, to two local YCR fund raising committees and to the annual meeting of all YCR collection committees.

NA
Year(s) Of Engagement Activity 2011
 
Description York - Local patient support groups and schools 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Schools
Results and Impact Regular non-scientific account of research to local patient support groups and local schools

None
Year(s) Of Engagement Activity 2010
 
Description York - Masonic Lodge 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Dr Davide Pellacani attended a dinner of the local Masonic Lodge who have sponsored some of his research as part of a grant to YCR.

NA
Year(s) Of Engagement Activity 2011
 
Description York - Presentation to Masonic Grand Charity 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Presented talks at Masonic functions and assisted in preparing an information sheet for Masons on benefits of being screened for prostate cancer

Three non-symptomatic tumours from 1000 patients have been detected.
Year(s) Of Engagement Activity 2010
 
Description York - Prostate Cancer Charity 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact A formal lecture on new screening methods for prostate cancer to the Prostate Cancer Charity Patients' Forum held at the Central Hall Westminster

NA
Year(s) Of Engagement Activity 2011
 
Description York - SKY News and Radio 4 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Appearance on SKY News and contribution to the Radio 4 programme Saving the Earth, discussing the use of jellyfish proteins for cancer imaging.

NA
Year(s) Of Engagement Activity 2011